These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 620402)
1. In vitro plasminogen activator activity in human brain tumors. Tucker WS; Kirsch WM; Martinez-Hernandez A; Fink LM Cancer Res; 1978 Feb; 38(2):297-302. PubMed ID: 620402 [TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assays. Camiolo SM; Greco WR Cancer Res; 1986 Apr; 46(4 Pt 1):1788-94. PubMed ID: 3081257 [TBL] [Abstract][Full Text] [Related]
3. Serpin inhibitors of urokinase and thrombin in normal rat brain and the 9L brain tumor: evidence for elevated expression of protease nexin I-like inhibitor and a novel sodium dodecyl sulfate-activated tumor antithrombin. Rao JS; Baker JB; Morantz RA; Kimler B; Evans R; Festoff BW Cancer Res; 1990 Aug; 50(16):5039-44. PubMed ID: 2116223 [TBL] [Abstract][Full Text] [Related]
4. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro. Matsuo O; Rijken DC; Collen D Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339 [TBL] [Abstract][Full Text] [Related]
5. Human hepatoma cell line plasminogen activator. Levin EG; Fair DS; Loskutoff DJ J Lab Clin Med; 1983 Oct; 102(4):500-8. PubMed ID: 6311924 [TBL] [Abstract][Full Text] [Related]
6. Hybrid molecules: insights into plasminogen activator function. Runge MS; Bode C; Haber E; Quertermous T Mol Biol Med; 1991 Apr; 8(2):245-55. PubMed ID: 1806766 [TBL] [Abstract][Full Text] [Related]
7. In vitro studies on the fibrinolytic, thrombolytic and fibrinogenolytic properties of a tissue plasminogen activator from guinea pig keratocytes. Electricwala A; Ling RJ; Sutton PM; Griffiths B; Riley PA; Atkinson T Thromb Haemost; 1985 Apr; 53(2):200-3. PubMed ID: 4040659 [TBL] [Abstract][Full Text] [Related]
8. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro. Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946 [TBL] [Abstract][Full Text] [Related]
10. Growth factor-dependent proliferation and invasion of muscle satellite cells require the cell-associated fibrinolytic system. Fibbi G; D'Alessio S; Pucci M; Cerletti M; Del Rosso M Biol Chem; 2002 Jan; 383(1):127-36. PubMed ID: 11928807 [TBL] [Abstract][Full Text] [Related]
11. Reversion of the invasive phenotype of transformed human fibroblasts by anti-messenger oligonucleotide inhibition of urokinase receptor gene expression. Quattrone A; Fibbi G; Anichini E; Pucci M; Zamperini A; Capaccioli S; Del Rosso M Cancer Res; 1995 Jan; 55(1):90-5. PubMed ID: 7805047 [TBL] [Abstract][Full Text] [Related]
12. Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator. Kurokawa T; Iwasa S; Kakinuma A; Stassen JM; Lijnen HR; Collen D Thromb Haemost; 1991 Dec; 66(6):684-93. PubMed ID: 1796414 [TBL] [Abstract][Full Text] [Related]
13. Plasminogen activator mediated degradation of subendothelial extracellular matrix by human squamous carcinoma cell lines. Niedbala MJ; Sartorelli AC Cancer Commun; 1990; 2(5):189-99. PubMed ID: 2142433 [TBL] [Abstract][Full Text] [Related]
14. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors. Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751 [TBL] [Abstract][Full Text] [Related]
15. Immunological characterization of plasminogen activators in human mixed saliva. Kjaeldgaard A; Kjaeldgaard M Acta Physiol Scand; 1986 Mar; 126(3):443-7. PubMed ID: 3515850 [TBL] [Abstract][Full Text] [Related]
16. Purification and characterization of the plasminogen activator secreted by a rat brain tumor cell line in culture. Bykowska K; Rijken DC; Collen D Thromb Haemost; 1981 Oct; 46(3):642-4. PubMed ID: 7198301 [TBL] [Abstract][Full Text] [Related]
17. Extracellular matrix production and degradation by adenoid cystic carcinoma cells: participation of plasminogen activator and its inhibitor in matrix degradation. Shirasuna K; Saka M; Hayashido Y; Yoshioka H; Sugiura T; Matsuya T Cancer Res; 1993 Jan; 53(1):147-52. PubMed ID: 8380125 [TBL] [Abstract][Full Text] [Related]
18. Molecular species of plasminogen activators secreted by normal and neoplastic human cells. Wilson EL; Becker ML; Hoal EG; Dowdle EB Cancer Res; 1980 Mar; 40(3):933-8. PubMed ID: 7193517 [TBL] [Abstract][Full Text] [Related]
19. Regulation of human squamous cell carcinoma plasma membrane associated urokinase plasminogen activator by epidermal growth factor. Niedbala MJ; Bajetta S; Carbone R; Sartorelli AC Cancer Commun; 1990; 2(9):317-24. PubMed ID: 2169831 [TBL] [Abstract][Full Text] [Related]
20. Plasminogen activators in human malignant melanoma. Markus G; Kohga S; Camiolo SM; Madeja JM; Ambrus JL; Karakousis C J Natl Cancer Inst; 1984 Jun; 72(6):1213-22. PubMed ID: 6374238 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]